Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compound acetylisovalery tylosin tartrate pellet and preparation method thereof

A technology of tyvanectin and tartaric acid, which is applied in the direction of pharmaceutical formulations, antibacterial drugs, and medical preparations containing active ingredients, etc., which can solve the problem of increasing the number of administrations, increasing the labor intensity, low bioavailability of drugs, and not reaching the ideal Effectiveness and other issues, to achieve the effect of masking bad smell, prolonging the drug action time, and reducing labor intensity

Inactive Publication Date: 2013-09-04
GUANGDONG WENS DAHUANONG BIOTECH
View PDF4 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] At present, the common tivalamectins on the market are ordinary premixes and soluble powders. Due to the simple preparation process, the bioavailability of the drug is low, and it is easily affected by gastric acid, and the drug itself is easy to cause serious damage to the gastrointestinal tract. Ordinary preparations have a strong smell and bitter taste and are easy to scatter, resulting in poor palatability and reduced feed intake, so that the curative effect of the drug is reduced, and the desired effect cannot be achieved; A variety of ingredients such as acidifiers, high trace elements, electrolytes, etc. undergo chemical reactions, reducing the efficacy of the drug, and the number of administrations of ordinary preparations increases the labor intensity; and the Chinese patent application number "201110009247.6" discloses a Tylvalerin injection for breeding pigs and preparation method thereof, each 100 ml of injection contains 20 grams of acetylisovaleryl tylosin tartrate, 20-35 grams of propylene glycol, and 10-15 grams of N,N-diformyl acetamide , 2 to 4 grams of benzyl alcohol, 0.1 to 1.0 grams of di-tert-butyl p-cresol and the balance of glycerol triacetate
However, this kind of tivalamectin injection for pigs still has the disadvantages that the labor intensity is high, and the injection will cause strong stress to pigs.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] A compound tyvalomectin tartrate pellet, comprising a coating and a drug-loaded core, the drug-loaded core is a microparticle with a size not greater than 30 mesh, wherein the drug-loaded core contains the following components in weight percentage: 2%; sulfamethazine 2%; lactose 10%; corncob flour 10%; starch 58%; microcrystalline cellulose 15%; granulation binder 3%.

[0032] Wherein, the granulation binder is a gelatin binder. The coating weight is 2% of the total weight of the compound tyvalectin tartrate pellets, wherein the coating material is hydroxypropyl methylcellulose.

[0033] The preparation method of described compound tyvalactin tartrate pellets comprises the following specific steps:

[0034] 1) Weigh the following components according to the following weight percentages: 2% tyvalectin tartrate, 2% sulfamethazine, 10% lactose, 10% corncob powder, 58% starch, 15% microcrystalline cellulose %, gelatin granulation binder 3%. Mix tyvalactin tartrate, sulfa...

Embodiment 2

[0039] A compound tyvalomectin tartrate pellet, comprising a coating and a drug-loaded core, the drug-loaded core is a microparticle with a size not greater than 30 mesh, wherein the drug-loaded core contains the following components in weight percentage: 5%, sulfamethazine 5%, lactose 15%, corn cob flour 10%, starch 44%, microcrystalline cellulose 15%, granulation binder 6%.

[0040] Wherein, the granulation binder is a starch binder. The coating weight is 3% of the total weight of the compound tyvalactin tartrate pellets, wherein the coating material is methyl cellulose.

[0041] The preparation method of described compound tyvalactin tartrate pellets comprises the following specific steps:

[0042] 1) Weigh the following components according to the following weight percentages: 5% tyvalectin tartrate, 5% sulfamethazine, 15% lactose, 10% corncob powder, 44% starch, 15% microcrystalline cellulose %, starch binder 6%. Mix tyvalactin tartrate, sulfamethazine, lactose, cornco...

Embodiment 3

[0047] A compound tyvalomectin tartrate pellet, comprising a coating and a drug-loaded core, the drug-loaded core is a microparticle with a size not greater than 30 mesh, wherein the drug-loaded core contains the following components in weight percentage: 10%, sulfamethazine 10%, lactose 10%; corn cob flour 15%, starch 31%, microcrystalline cellulose 20%, granulation binder 4%.

[0048] Wherein, the granulation binder is a mixture of polyvinylpyrrolidone and polyethylene glycol. The coating weight is 3% of the total weight of the compound tyvalectin tartrate pellets, wherein the coating material is hydroxypropyl methylcellulose.

[0049] The preparation method of described compound tyvalactin tartrate pellets comprises the following specific steps:

[0050] 1) Weigh the following components according to the following weight percentages: 10% tyvalectin tartrate, 10% sulfamethazine, 10% lactose, 15% corncob powder, 31% starch, 20% microcrystalline cellulose %, polyvinylpyrroli...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a compound acetylisovalery tylosin tartrate pellet. The compound acetylisovalery tylosin tartrate pellet is made by wrapping a drug-loading pellet core by adopting a coating material, wherein the drug-loading pellet core comprises the following components in percentage by weight: 1-30% of acetylisovalery tylosin tartrate, 1-30% of sulfadimidine, 5-20% of lactose, 5-25% of corncob powder, 10-60% of starch, 15-35% of microcrystalline cellulose and 0.5-12% of pelletizing binding agent; and weight of the coating material is not more than 8% of the total weight of the compound acetylisovalery tylosin tartrate pellet. The compound acetylisovalery tylosin tartrate pellet has a better clinical treatment effect, application amount of acetylisovalery tylosin tartrate can be reduced, and production cost can be saved; and drug release can be delayed, drug action time can be prolonged, and long-acting effect can be achieved, so that administration frequency is reduced and labour intensity can be alleviated.

Description

[0001] technical field [0002] The invention relates to a compound tyvalectin tartrate pellet and a preparation method thereof, belonging to the technical field of veterinary drug preparations. [0003] Background technique [0004] Acetylisovalery Tylosin Tartrate (Acetylisovalery Tylosin Tartrate) is a brand-new macrolide antibiotic commercialized by Echo Animal Health Products Co., Ltd., UK. It is a derivative of tylosin A produced by chemical modification, and has strong antibacterial activity against mycoplasma, spirochete, most gram-positive bacteria and some gram-negative bacteria, especially against mycoplasma ; Mainly used to prevent mycoplasma infection in chickens, turkeys and other animals, pig dysentery, infectious pleuropneumonia, panting disease, proliferative enteritis (PPE), etc. It is a special antibiotic for livestock and poultry. [0005] At present, the common tivalamectins on the market are ordinary premixes and soluble powders. Due to the simple pre...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61K9/16A61P31/04A61K31/635
Inventor 刘小艳方烦虎陈瑞爱袁照红湛穗璋
Owner GUANGDONG WENS DAHUANONG BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products